Yahoo · Oct 22, 2026
Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment
The treatment targets the SCN1A gene, which helps the brain produce a protein that controls electrical activity and prevents seizures
XB
AMEX · XBI
SPDR S&P Biotech ETF
Financial Services · Asset Management
$155.98
Down-$1.81 (-1.15%)
Updated Nov 1, 2026, 7:11 AM
SID Score
5.9/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 6.38B
- P/E ratio
- —
- Dividend yield
- 0.03%
- 52-week range
- $118.19 – $169.89
- Volume
- 9.1M
- Avg. volume
- 10.76M
Price performance · XBI
XBI price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
XBI closed at $155.98 after 20 trading sessions, down 0.13% for the selected period.
- Last close
- $155.98
- Period change
- -0.13%
- Period low
- $144.32
- Period high
- $157.79
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $156.68 | $159.76 | $154.22 | $155.98 | 9.1M |
| Oct 29, 2026 | $157.64 | $160.29 | $156.43 | $157.79 | 10.93M |
| Oct 28, 2026 | $153.27 | $157.55 | $152.83 | $157.51 | 9.11M |
| Oct 27, 2026 | $150.35 | $154.92 | $149.27 | $154.84 | 8.67M |
| Oct 26, 2026 | $150.42 | $151.83 | $149.49 | $150.47 | 4.82M |
| Oct 23, 2026 | $150.46 | $150.705 | $147.635 | $149.54 | 6.61M |
| Oct 22, 2026 | $152.25 | $154.44 | $149.69 | $151.64 | 11.6M |
| Oct 21, 2026 | $153.37 | $155.78 | $152.69 | $152.78 | 8.3M |
| Oct 20, 2026 | $148.03 | $153.98 | $147.75 | $153.24 | 12.37M |
| Oct 19, 2026 | $145.88 | $148.63 | $145.29 | $147.86 | 8.39M |
| Oct 16, 2026 | $149.89 | $150.225 | $143.8492 | $144.32 | 11.76M |
| Oct 15, 2026 | $147.71 | $150.86 | $146.93 | $149.78 | 11.51M |
| Oct 14, 2026 | $146.17 | $148.82 | $145.26 | $146.77 | 10.38M |
| Oct 13, 2026 | $150.52 | $150.89 | $146.70 | $146.80 | 9.75M |
| Oct 12, 2026 | $153.43 | $154.12 | $151.10 | $151.40 | 6.05M |
| Oct 9, 2026 | $149.32 | $154.50 | $149.03 | $153.77 | 12.14M |
| Oct 8, 2026 | $149.00 | $149.69 | $146.01 | $149.29 | 12.92M |
| Oct 7, 2026 | $149.37 | $152.40 | $148.63 | $150.23 | 9.54M |
| Oct 6, 2026 | $156.87 | $157.47 | $149.68 | $150.90 | 17.22M |
| Oct 5, 2026 | $155.56 | $156.73 | $152.56 | $156.19 | 6.99M |
Latest XBI news
The latest Smart Investors Daily articles mentioning XBI.
Stock researchCompany · Overview
Company
Market Activity
Research & News
XBI research
Overview
Company profile and research snapshot.
Company profile
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Oct 22, 2026
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
Both of these ETFs look the part, but only one is truly the better buy for investors.
Yahoo · Oct 20, 2026
Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million
Traders poured tens of millions into a triple-leveraged biotech fund in a single day, a move that looks like bold conviction until you see what that same bet returned over five years.
Yahoo · Oct 14, 2026
UNH Stock Outpaces S&P 500 In 2026, Eyes Best Year Since Pandemic — CFO Says Wall Street May Be Missing 2027 Upside
CFO Wayne DeVeydt called the lower end of the company’s 13% to 16% long-term earnings growth target a “reasonable starting point.”
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
